Protective effect of paraoxonase 1 of high-density lipoprotein in type 2 diabetic patients with nephropathy

被引:12
|
作者
Li, Chengjiang [1 ]
Gu, Qing [1 ]
机构
[1] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Med, Hangzhou 310003, Zhejiang, Peoples R China
关键词
high-density lipoprotein; nephropathy; paraoxonase; 1; peroxide; type; 2; diabetes; CORONARY-HEART-DISEASE; OXIDATIVE STRESS; OXIDIZED LDL; RISK-FACTORS; HDL; SERUM; FRAMINGHAM; ASSOCIATION; PLASMA; PON1;
D O I
10.1111/j.1440-1797.2008.01035.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
P>Aim: Paraoxonase 1 (PON1) is an important antioxidative enzyme associated with high-density lipoproteins (HDL). Recent data suggest that HDL antioxidative ability may be altered in type 2 diabetic patients. The aim of this study was, therefore, to investigate whether HDL-PON1 activity and HDL antioxidative ability were related to the presence and severity of diabetic nephropathy. Methods: Sixty type 2 diabetic patients, who were subdivided into normoalbuminuria, microalbuminuria and macroalbuminuria, and 20 age- and sex-matched healthy controls were recruited. HDL was then isolated to measure PON1 activity, lipid peroxide and its ability in protecting low-density lipoprotein (LDL) from oxidation. Results: HDL-PON1 activity and HDL antioxidative ability in protecting LDL from oxidation was preserved in diabetic patients with normoalbuminuria, but significantly decreased in those with microalbuminuria or macroalbuminuria. HDL peroxide was comparable between healthy controls and normoalbuminuric patients, but significantly increased in those with microalbuminuria or macroalbuminuria. On multiple analyses, urinary protein was an independent negative determinant of HDL-PON1 activity, and HDL-PON1 activity was positively associated with HDL antioxidative ability, and negatively associated with HDL peroxide. Conclusion: HDL-PON1 activity is decreased in type 2 diabetic patients with incipient or overt nephropathy, which relates to the reduced HDL antioxidative ability in protecting LDL from oxidation and increased peroxide in HDL.
引用
收藏
页码:514 / 520
页数:7
相关论文
共 50 条
  • [41] Pharmacogenetics of paraoxonase activity: elucidating the role of high-density lipoprotein in disease
    Kim, Daniel Seung
    Marsillach, Judit
    Furlong, Clement E.
    Jarvik, Gail P.
    PHARMACOGENOMICS, 2013, 14 (12) : 1495 - 1515
  • [42] Paraoxonase 1 overexpression in mice and its effect on high-density lipoproteins
    Oda, MN
    Bielicki, JK
    Ho, TT
    Berger, T
    Rubin, EM
    Forte, TM
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 290 (03) : 921 - 927
  • [43] Consumption of wonderful variety pomegranate juice and extract by diabetic patients increases paraoxonase 1 association with high-density lipoprotein and stimulates its catalytic activities
    Rock, Wasseem
    Rosenblat, Mira
    Miller-Lotan, Rachel
    Levy, Andrew P.
    Elias, Mazen
    Aviram, Michael
    JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 2008, 56 (18) : 8704 - 8713
  • [44] Atorvastatin effect on high-density lipoprotein-associated paraoxonase activity and oxidative DNA damage
    Harangi, M
    Seres, I
    Varga, Z
    Emri, G
    Szilvássy, Z
    Paragh, G
    Remenyik, É
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 60 (10) : 685 - 691
  • [45] Atorvastatin effect on high-density lipoprotein-associated paraoxonase activity and oxidative DNA damage
    Mariann Harangi
    Ildikó Seres
    Zsuzsa Varga
    Gabriella Emri
    Zoltán Szilvássy
    György Paragh
    Éva Remenyik
    European Journal of Clinical Pharmacology, 2004, 60 : 685 - 691
  • [46] Lack of association between serum paraoxonase 1 activity and circulating oxidized low-density lipoprotein in type 2 diabetic patients
    Lucchesi, D.
    Pucci, L.
    Fotino, C.
    Triscornia, S.
    Longo, V.
    Penno, G.
    Del Prato, S.
    Miccoli, R.
    ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 528 - 528
  • [47] Lack of association between serum paraoxonase 1 activity and circulating oxidized low-density lipoprotein in Type 2 diabetic patients
    Pucci, L
    Lucchesi, D
    Nencioni, S
    Triscornia, S
    Fotino, C
    Baldassari, E
    Penno, G
    Miccoli, R
    Giovannitti, G
    Longo, V
    Del Prato, S
    DIABETOLOGIA, 2004, 47 : A203 - A204
  • [48] THE CONCENTRATION OF HIGH-DENSITY LIPOPROTEIN IN PATIENTS WITH TYPE-IV HYPERLIPOPROTEINEMIA AND THE EFFECT OF CLOFIBRATE
    BROOK, JG
    LAVY, A
    AVIRAM, M
    ZINDER, O
    ATHEROSCLEROSIS, 1980, 36 (04) : 461 - 469
  • [49] No Improvement of High-Density Lipoprotein (HDL) Vasorelaxant Effect Despite Increase in HDL Cholesterol Concentration in Type 2 Diabetic Patients Treated With Glitazones
    Persegol, Laurence
    Duvillard, Laurence
    Monier, Serge
    Brindisi, Marie-Claude
    Bouillet, Benjamin
    Petit, Jean-Michel
    Verges, Bruno
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2014, 99 (10): : E2015 - E2019
  • [50] Protective Role of High-Density Lipoprotein in Multiple Sclerosis
    Damiza-Detmer, Agnieszka
    Pawelczyk, Malgorzata
    Glabinski, Andrzej
    ANTIOXIDANTS, 2024, 13 (11)